AMG-732 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving AMG-732 Growth

• Clinically Validated IGF-1R Target with Proven Disease Biology

AMG 732 targets IGF-1R, a receptor that plays a central role in the pathogenesis of TED by promoting orbital fibroblast activation, inflammation, adipogenesis, and tissue remodeling. The success of the first approved IGF-1R inhibitor for TED has clinically validated this pathway, substantially reducing biological risk for AMG 732. By entering a pathway with proven efficacy, Amgen has the opportunity to develop a differentiated next-generation therapy with potential improvements in efficacy, dosing, or safety. Amgen identifies AMG 732 as an IGF-1R-targeting monoclonal antibody in its development pipeline.

• Advancement into Phase II Development

A major value driver is the program's advancement into Phase II clinical trials. According to Amgen's 2025 and 2026 financial reports, Phase II enrollment is ongoing in patients with moderate-to-severe active TED, reflecting continued investment in the program and confidence in its early clinical profile. Successful proof-of-concept data from this study would substantially increase the probability of late-stage development and potential partnering or commercialization opportunities.

• Significant Unmet Need in Moderate-to-Severe Thyroid Eye Disease

TED remains a debilitating autoimmune disease characterized by proptosis, diplopia, orbital inflammation, pain, and vision impairment. Although an approved IGF-1R-targeted therapy has transformed treatment, not all patients achieve durable responses, and treatment limitations related to infusion schedules, adverse events, and accessibility persist. Consequently, there remains demand for additional biologics capable of improving efficacy, tolerability, or convenience, creating commercial opportunity for AMG 732 if it demonstrates differentiation in clinical studies. Published reviews continue to recognize IGF-1R inhibition as one of the most important therapeutic advances in TED management.

• Strong Development and Commercialization Capabilities of Amgen

Amgen possesses extensive expertise in developing and globally commercializing monoclonal antibodies across immunology and inflammation. The company's established biologics manufacturing network, regulatory experience, and worldwide commercial infrastructure reduce development risk and position AMG 732 for efficient global commercialization if approved. Continued inclusion of AMG 732 in Amgen's strategic clinical pipeline underscores the company's commitment to advancing the program.

• Opportunity for Lifecycle Expansion Beyond TED

The IGF-1R signaling pathway has been implicated in additional autoimmune and fibro-inflammatory disorders. Although AMG 732 is currently being evaluated only in TED, successful demonstration of safety and efficacy could support future investigation in related indications where IGF-1R contributes to disease pathogenesis. Such lifecycle expansion would increase the product's long-term commercial potential beyond its initial orphan indication, although no additional indications have been formally announced by Amgen.

AMG-732 Recent Developments

An open-label, rollover study (NCT07438405) was initiated to evaluate AMG-732 efficacy specifically in participants defined as primary proptosis non-responders or those who relapsed during safety follow-ups from parent trials.

“AMG-732 Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of AMG-732 for potential indication like Graves ophthalmopathy in the 7MM. A detailed picture of AMG-732’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the AMG-732 for potential indications. The AMG-732 market report provides insights about AMG-732’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current AMG-732 performance, future market assessments inclusive of the AMG-732 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of AMG-732 sales forecasts, along with factors driving its market.

AMG-732 Drug Summary

AMG-732 is an investigational biologic therapy being developed by Amgen for the treatment of moderate-to-severe active thyroid eye disease (TED). Although Amgen has not yet publicly disclosed the molecule's precise target or mechanism of action, AMG-732 is designed as a subcutaneous injectable therapy intended to reduce the autoimmune inflammation and orbital tissue remodeling that characterize TED. The drug is currently being evaluated in a Phase 1/2 randomized, double-masked, placebo-controlled, multicenter clinical trial assessing its safety, tolerability, pharmacokinetics, and efficacy in healthy volunteers and patients with active TED, followed by an open-label Phase 2 rollover study for participants who did not achieve an adequate response or experienced relapse in the parent trial. As of 2026, AMG-732 remains an investigational candidate with no regulatory approvals, and ongoing studies are evaluating its potential to improve key clinical outcomes such as proptosis reduction, disease activity, and overall ocular symptoms in patients with thyroid eye disease. The report provides AMG-732’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the AMG-732 Market Report

The report provides insights into:

• A comprehensive product overview including the AMG-732 MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy.
• Elaborated details on AMG-732 regulatory milestones and other development activities have been provided in AMG-732 market report.
• The report also highlights AMG-732‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The AMG-732 market report also covers the patents information, generic entry and impact on cost cut.
• The AMG-732 market report contains current and forecasted AMG-732 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The AMG-732 market report also features the SWOT analysis with analyst views for AMG-732 in potential indications.

Methodology

The AMG-732 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AMG-732 Analytical Perspective

• In-depth AMG-732 Market Assessment

This AMG-732 sales market forecast report provides a detailed market assessment of AMG-732 for potential indication like Graves ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted AMG-732 sales data uptil 2034.

• AMG-732 Clinical Assessment

The AMG-732 market report provides the clinical trials information of AMG-732 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

AMG-732 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

AMG-732 Market Potential & Revenue Forecast

• Projected market size for the AMG-732 and its key indications
• Estimated AMG-732 sales potential (AMG-732 peak sales forecasts)
• AMG-732 Pricing strategies and reimbursement landscape

AMG-732 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• AMG-732 Market positioning compared to existing treatments
• AMG-732 Strengths & weaknesses relative to competitors

AMG-732 Regulatory & Commercial Milestones

• AMG-732 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

AMG-732 Clinical Differentiation

• AMG-732 Efficacy & safety advantages over existing drugs
• AMG-732 Unique selling points

AMG-732 Market Report Highlights

• In the coming years, the AMG-732 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The AMG-732 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AMG-732’s dominance.
• Other emerging products for Graves ophthalmopathy are expected to give tough market competition to AMG-732 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AMG-732 in potential indications.
• Analyse AMG-732 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted AMG-732 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of AMG-732 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of AMG-732? How strong is AMG-732’s clinical and commercial performance?
• What is AMG-732’s clinical trial status in each individual indications such as Graves ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AMG-732 Manufacturers?
• What are the key designations that have been granted to AMG-732 for potential indications? How are they going to impact AMG-732’s penetration in various geographies?
• What is the current and forecasted AMG-732 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of AMG-732 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to AMG-732 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is AMG-732? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.